OXC-101 as a new therapy for AML
| Reference number | |
| Coordinator | Oxcia AB |
| Funding from Vinnova | SEK 2 995 000 |
| Project duration | April 2023 - May 2025 |
| Status | Ongoing |
| Venture | Swelife and Medtech4Health - Collaborative Projects for Improved Health |
| Call | Swelife and Medtech4Health - Collaborative projects for better health autumn 2022 |
Purpose and goal
Oxcia is investigating OXC-101, a mitotic MTH1 inhibitor with an innovative mechanism of action, in a clinical phase 1 study in AML. Preliminary data is promising in a very fragile and advanced patient population. In this project, Oxcia collaborates closely with Karolinska Institute, Karolinska University Hospital and Örebro University Hospital to demonstrate efficacy in monotherapy as well as investigate efficacy and safety in combination with chemotherapy in refractory/relapsed AML.
Expected effects and result
This is a critical step to be able to take the project further in development. The project has potential to improve AML treatment and fuel innovation in Swedish Life Science.
Planned approach and implementation
The Project is divided into three work packages (WP): WP1 includes all regulatory and ethical preparations for approval of the clinical study. WP2 is the execution of the clinical study. Precision medicine screening is included in the clinical trial as a way to identify responders/non-responders and as a method to stratify patients in the future. The third WP is the business development and project management , including for instance business- commercialization plan, presentation of the project for potential collaborators/Pharma.